CeriBell, Inc. (NASDAQ: CBLL) is a Healthcare company (Medical - Devices) with a market capitalization of $1.0B. The Maz Rating grades it against the other companies in its sector.
CeriBell, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $25.97, CeriBell, Inc. trades at 9.4x sales and 8.7x book value. Over the last twelve months it generated about $107M of revenue and a net loss of $74M. It runs a gross margin of 89.3%, an operating margin of -69.8% and a net margin of -68.0%. It shows return on equity of -54.5%, return on invested capital of -54.4% and a free cash flow yield of -5.8%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 8.18. Over the past 52 weeks the share price ranged from $12.65 to $28.89, with a beta of 0.86.
CeriBell, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, CeriBell, Inc. (CBLL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.08% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.2% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.08% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.2% / 33% · Receivables / Mkt Cap (36m) 1.85% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 2.08% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.2% / 33.33% · Receivables / Mkt Cap (24m) 1.85% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 11.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 78.5% / 33.33% · Receivables / Avg Assets (4Q) 9.27% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 12.8% / 33.33% · (Cash+ST Inv) / Total Assets 75.1% / 33.33% · (Cash+Recv) / Total Assets 86.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, CeriBell, Inc. (CBLL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. CeriBell, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
CeriBell, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.